Published: May 18, 2021 By Alex Keown
Three companies on three separate continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.
Hummingbird Bioscience Raises $125 Million
Singapore-based
raised $125 million in an oversubscribed Series C financing round. The funds will be used to support the development of the company’s two lead programs and advance its early-stage clinical research.
Hummingbird’s two lead assets are HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, a first-in-class anti-VISTA neutralizing antibody for advanced solid tumors.
The funds will also be used to expand the capabilities of Hummingbird s proprietary Rational Antibody Discovery platform and progress the development of its next-generation pipeline of precision therapeutics, including HMBD-009, a BCMA-TACI dual-specific T cell engager.
Hummingbird Bioscience buzzes with $150M series C led by Novo Holdings
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Frazier Growth Buyout Announces the Promotions of Jeremy Janson and Shyamal Swami to Vice President
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Alcresta Therapeutics Announces Publication of NASPGHAN Position Paper Recommending RELiZORB® in Children with Chronic Pancreatitis
News provided by
Share this article
Share this article
NEWTON, Mass., Feb. 23, 2021 /PRNewswire/ Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced publication of a position paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Pancreas Committee recommending the use of RELiZORB
® (immobilized lipase cartridge), a first-of-its-kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase. Their recommendation further reinforces the clinical benefits of RELiZORB (immobilized lipase cartridge) in patients with fat malabsorption conditions beyond cystic fibrosis.